STUDY PURPOSE: This observational study describes the three-year survival outcome of consecutively recruited advanced stage breast, colorectal, ovarian and pancreatic cancer patients receiving advanced integrative oncology (AIO) treatment at one of the participating North American advanced integrative oncology specialist clinics. This study also aims to describe AIO treatments recommended by naturopathic oncologists for these advanced stage cancer patients and pilot the collection and evaluation of health-related quality of life data on a subset of Canadian AIO-treated patients.
STUDY POPULATION: All stage 4 breast or colorectal cancer patients and all stage 3 or 4 ovarian and pancreatic cancer patients seeking care at the participating AIO clinical sites meeting inclusion/exclusion criteria are eligible to participate in this study.
STUDY PROCEDURES: Other than a first office visit at a participating AIO clinic, there are no study visits or procedures required except for completing enrollment documents. Study data will be collected from the patient’s AIO clinic and conventional oncology records. If you’re interested in participating, contact one of the naturopathic oncologists listed below to schedule an appointment.
PARTICIPATING AIO CLINICAL SITES AND PRINCIPAL INVESTIGATORS:
Shelby Naturopathy PLLC (SNP), Seattle, Washington – Dr. Leanna Standish
Naturopathic Specialists, LLC (NSL), Scottsdale, Arizona – Dr. Dan Rubin
Salish Integrative Oncology Care Center (SIOCC), Fife, Washington
Hawaii Integrative Oncology, Lokahi Health Center (LHC), Kailua Kana, Hawaii – Dr. Michael Traub
Ottawa Integrative Cancer Center (OICC), Ottawa, Ontario – Dr. Dugald Seely
Vital Victoria Naturopathic Clinic Ltd. (VVNC), Victoria, British Columbia – Dr. Neil McKinney
Integrated Health Clinic Cancer Care Centre (IHCCC), Fort Langley, British Columbia – Dr. Gurdev Parmar
Marsden Centre for Excellence in Integrative Medicine, (MCEIM), Vaughan, Ontario – Dr. Eric Marsden
HealthSource Integrative Medical Centre (HSIMC(, Kitchener, Ontario – Dr. Michael Reid
ClinicalTrials.gov identifier: NCT02494037